Boswellia serrata is a tree native to much of India and the Punjab region extending into Pakistan. The resin it produces is sold as Indian frankincense, and Ayurvedic practice has used it for joint complaints for a very long time. What makes it interesting now is not the history. It is that boswellia has been through more controlled human trials for joint pain than most of the botanicals sitting next to it on a supplement shelf.
That does not mean the case is closed. It means there is something real to look at.
What the pooled evidence found
In 2020, Yu and colleagues published a systematic review and meta-analysis in BMC Complementary Medicine and Therapies. They pooled seven randomized controlled trials covering 545 patients with osteoarthritis.
Across those trials, boswellia beat placebo on every primary outcome measured:
| Outcome | Weighted mean difference | 95% CI | P |
|---|---|---|---|
| Pain (VAS) | −8.33 | −11.19 to −5.46 | <0.00001 |
| Pain (WOMAC) | −14.22 | −22.34 to −6.09 | 0.0006 |
| Stiffness (WOMAC) | −10.04 | −15.86 to −4.22 | 0.0007 |
| Function (WOMAC) | −10.75 | −15.06 to −6.43 | <0.00001 |
| Lequesne Index | −2.27 | −3.08 to −1.45 | <0.00001 |
The doses in those trials ran from 100 mg to 250 mg, and the authors pointed to at least four weeks of continuous use as the treatment duration to look at. Keep those numbers in mind, because they come back later and they are smaller than you would expect.
The trial that tested two doses
Most single studies test one dose against placebo, which tells you whether something works but not whether more of it works better. Two trials did it differently, and together they are the most useful thing in this literature.
Sengupta and colleagues, 2008, in Arthritis Research & Therapy. Seventy-five patients with knee osteoarthritis, 90 days, comparing placebo against 100 mg and 250 mg daily of a boswellia extract standardized to 30% AKBA. At 90 days the 250 mg group reported a 65.94% drop in visual analog pain scores and a 31.34% improvement in functional index. Synovial fluid MMP-3, an enzyme involved in cartilage breakdown, fell 46.4%.
The speed surprised the authors. In the 250 mg group, pain and functional ability improved significantly within seven days.
A 2024 trial in Frontiers in Pharmacology. Ninety-eight people with knee osteoarthritis completed 90 days on either placebo, 150 mg of boswellia extract twice daily, or 300 mg twice daily. Pain on the VAS fell 45.3% on the lower dose and 61.9% on the higher one. WOMAC stiffness improved 65.6% and 68.9%. Function improved 68.8% and 74.2%.
In both trials the higher dose did more than the lower one. That is what you expect from something actually doing the work rather than riding a placebo effect.
The number on the label is not the number that matters
Here is the part that gets left out of almost every article about boswellia.
Its activity is attributed largely to boswellic acids, and in particular to AKBA, acetyl-11-keto-beta-boswellic acid. Raw boswellia resin contains only a small fraction of it. The extract Sengupta tested was standardized to 30% AKBA, which is a lot. That concentration is precisely why the trial could show results at 100 mg and 250 mg.
So 400 mg of an unstandardized extract is not automatically stronger than 250 mg of a concentrated one. Depending on the raw material it could deliver a fraction of the AKBA. Milligrams on a panel tell you how much powder went into the capsule. They do not tell you how much of the active compound came with it.
If you are comparing boswellia products, the standardization percentage is the number to look for. Many labels do not print it.
How much is in MicroFree
Each serving of MicroFree contains 400 mg of Boswellia serrata extract.
Against the trials, that milligram count sits comfortably inside the studied range and well under the ceiling NCCIH lists as likely safe by mouth, which is up to 1,000 mg daily for six months.
Our label does not currently state a boswellic acid or AKBA percentage. We would rather flag that than write around it. It is the same question we would tell you to ask of any other brand.
What the research still cannot tell you
NCCIH, the U.S. federal body that reviews this kind of evidence, is direct about the limits. Several studies suggest boswellia taken by mouth may help with inflammation and pain in osteoarthritis, but larger and higher quality studies are needed. Their broader position is that there is not enough high quality evidence to determine whether boswellia is useful for any health condition.
Both things are true at once. The trials that exist point the same direction, and the trials that exist are small. Seven studies and 545 people is a respectable base for a botanical. It is a rounding error next to what sits behind a prescription drug.
The other gap is time. The longest of these trials ran 90 days. Nobody has followed people taking boswellia for years, so nobody can tell you what happens after that.
Safety, and who should ask first
Across the pooled trials boswellia was generally well tolerated. The Yu meta-analysis called it an effective and safe option while noting that adverse event reporting in these studies was thin, and that an absence of reported problems is not the same as proof there are none. Where side effects did appear they were mild and mostly digestive.
NCCIH flags one interaction worth taking seriously. If you take medication for asthma, talk to your provider before starting boswellia. More generally, if you are on prescription medication, pregnant, or managing a diagnosed condition, that conversation belongs before you add any supplement, not after.
The short version
Boswellia is one of the better supported joint ingredients you can buy, and the support is still modest in absolute terms. Two separate trials found the higher dose outperformed the lower one. One saw movement within a week, most point to four weeks or more. And the milligram count on the front of a label means much less than the standardization behind it, which is the question to ask of any boswellia product, ours included.